Eli Lilly to Present Data of Taltz (ixekizumab) for Patients with Psoriatic Arthritis at EULAR 2020 #EULAR

Shots:

• Eli Lilly shared new results from a subgroup analysis of the P-IIIb/IV, 52-wks. SPIRIT-H2H study assessing Taltz vs Humira (adalimumab) in biologic-naïve patients with active PsA with 1EPs as ACR50 & PASI 100 @24wks. The study compares Taltz and Humira in subgroups of patients on monothx./ concomitant MTX/ concomitant MTX along with csDMARD including sulfasalazine, cyclosporine, or leflunomide
•  Results: MDA (49% vs 33%)/ (47% vs 47%)/ (47% vs 44%); 1EPs @52wks.(38% vs 19%) (39% vs 30%) (40% vs 29%); PASI 100 (66% vs 35%)/ (63% vs 44%)/ (64% vs 44%); ACR50 (51% vs 42%)/ (48% vs 56%)/ (49% vs 53%) respectively, data will be presented at EULAR on Jun 05, 2020. The safety profile for Taltz was consistent with knows safety of the therapy in patients with moderate to severe PsO and PsA
• Lilly also highlights results from two additional study SPIRIT-P2 study and P-III COAST-X study. The SPIRIT-P2 study demonstrated sustained improvement in signs and symptoms of PsA and P-III COAST-X study showed improvement in fatigue, spinal pain and stiffness @16wks.in patients with active nr-axSpA

Click here to read full press release/ article | Ref: Eli Lilly | Image: Twitter